FDA
-
-
-
-
-
-
-
Vanda submits FDA application for rare skin disorder drug
-
-
-
-
-
-
-
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
-
-
-
-
-
-
-
TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
-
-
-
-
-
-
-
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
GSK (GSK) and AnaptysBio (ANAB) Report Jemperli plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-free Survival
-
-
-
-
-
-
-
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
-
-
-
-
-
-
-
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
-
322,993 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

